Macquarie Group’s Sonoma Pharmaceuticals SNOA Stock Holding History

Macquarie Group’s Portfolio SNOA Stock Details SNOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-24	Closed	-$3K	–	1990
2018 Q4	$3K	Buy	+24	New	+$4.79K	﹤0.01%	2162

Other funds holding SNOA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Macquarie Group's SNOA Position: Q1 2019 in Review

Macquarie Group sold out of Sonoma Pharmaceuticals (SNOA) in Q1 2019, closing a stake of 24 shares — an estimated $3K sold.

Macquarie Group first reported a position in SNOA in Q4 2018 and held it in 1 quarter. The position peaked at $3K in Q4 2018. 22 funds tracked by Wall St. Rank hold SNOA as of Q1 2019.

Macquarie Group reported no remaining Sonoma Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Macquarie Group sold 24 Sonoma Pharmaceuticals shares in Q1 2019, an estimated $3K.
Macquarie Group first reported a position in Sonoma Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Macquarie Group's Sonoma Pharmaceuticals position peaked at $3K in Q4 2018.
22 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.